<html>
<head>
</head>
<body>
<p><span style="font-size: medium; font-family: arial, helvetica,
sans-serif;"><b>Nuvilex, Inc.’s Medical Marij. Subsidiary Receives
Excellent News with New Maryland Bill</b></span></p>
<p><span style="font-size: small; font-family: arial, helvetica,
sans-serif;"><span style="color: #008000; font-size: medium;"><b>Nuvilex,
Inc.</b></span> (OTCQB: <span style="color: #008000; font-size:
medium;"><b>NVLX</b></span>) and its subsidiary <span style="color:
#008000; font-size: medium;"><b>Medical Marij.Sciences, Inc.</b></span> got
some good news this week as Maryland lawmakers approved a bill permitting
medical marij. programs at research centers. The Silver Spring,
Maryland, biotechnology firm can take full advantage of the new measure as
soon as Maryland Governor, Martin O'Malley, signs the bill which he has
implied he is expected to do.</span></p>
<p><span style="font-size: small; font-family: arial, helvetica,
sans-serif;">There is a real snowball effect going on in the country
presently, and attitudes continue to shift more and more toward legalizing
marij. In a Pew Research Center poll late last week, 52% of Americans
now favor legalizing marij. This is the first time a majority of
Americans have supported marij.’s legalization in this poll, and
according to Pew, the question has been {addressed in polls since
1969. <span style="text-decoration: underline;"><strong> Assessments
are that the marij. business will reap incomes beating $3-billion by 2015
and twice that by 2018. </strong></span> The marij. snowball is
rolling and rolling fast!</span></p>
<p><span style="font-size: small; font-family: arial, helvetica,
sans-serif;">The Maryland legislature passed the bill overwhelmingly with a
vote of 42 to 4, joining a growing number of states and Washington, D.C.
that are now gaining a more promising approach to medical marij..
Feelings are plainly changing in the United States over the long-time
debated subject, and for potential patients this is great news.</span></p>
<p><span style="font-size: small; font-family: arial, helvetica,
sans-serif;">This information clears the way for Nuvilex to get working
diligently on its research at Medical Marij. Sciences. Prior to this
measure, company officials had a long road of development before them to
set up the accommodations skilled in completing the type of research the
subsidiary has planned and remain exempt from prosecution. This
measure will eradicate a large barrier.</span></p>
<p><span style="font-size: small; font-family: arial, helvetica,
sans-serif;"><span style="color: #008000;"><strong>Nuvilex</strong></span>
COO, Dr. Gerald Crabtree announced Maryland’s bill passing is good
news for the company’s future.</span></p>
<p><em><span style="font-size: small; font-family: arial, helvetica,
sans-serif;">“As a growing amount of states permit the use of marij.
for medicinal purposes, it enables more and more our planned search for
treatments for serious and deadly diseases, like pancreatic and brain
cancers that use components of the marij. plant. </span></em></p>
<p><em><span style="font-size: small; font-family: arial, helvetica,
sans-serif;">The fact that Maryland has recently approved a bill that will
permit research in the medical marij. area is essential to <span
style="color: #008000;"><strong>Nuvilex (NVLX)</strong></span>, in part,
because the company's head offices are positioned within the state.
This, in turn, should benefit us because we should be able to develop
alliances for our research efforts that are 'close to home' so to speak,
and in this way, R&D expenses for our medical marij. activities can be
optimized.”</span></em><br /><br /><span style="font-size: small;
font-family: arial, helvetica, sans-serif;"><br /><br /><span
style="font-size: x-small;">The usage of research materials published by
the publisher is done at your own risk. You are encouraged to do your
own research and due diligence before making any investment decision with
respect to the security discussed herein. The publisher has not been
compensated by any entity in connection with the distribution of these
materials. You should presume that as of the publication date of this
report or letter, the publisher, (possibly along with or through our
owners, affiliates, employees and/or consultants”) (collectively
referred to as the publisher) has a position in all stocks (and/or options
of the stock) covered herein that is consistent with the position set forth
in our report. In connection with NVLX, the publisher has taken a
long position. Following the distribution of any report or letter,
the publisher intends to continue engaging in transactions in the security
covered herein, and we may be long, short, and/or neutral at any time
hereafter regardless of our initial position and we preserve the right to
buy or sell all or part of our position at any time without notice.
This practice could result in our selling securities at any time before,
during, and/or after the publication of this report. The
publisher’s full disclaimer is available <a
href="http://drucatiss.biz/link.php?M=25671198&N=380&L=5&F=H">here</a>. <br
/><br /><a
href="http://drucatiss.biz/unsubscribe.php?M=25671198&C=77a9788be731e94e725ad330e2d3e268&L=62&N=380">Unsubscribe</a> <br
/><br />260 Peachtree Street NorthWest, STE 2200, Atlanta, Georg.
30303 U.S.A.</span></span></p>
<img
src="http://drucatiss.biz/open.php?M=25671198&L=62&N=380&F=H&image=.jpg"
height="1" width="10"></body>
</html>